

<b>Organization</b>	<b>Name of Organization / 会社名</b>
	Videregen Ltd
	<b>URL</b>
	<a href="http://www.videregen.com">www.videregen.com</a>
<b>Organization</b>	<b>Brief Descriptions of Organization / 会社概要</b>
	<p>Videregen is a clinical-stage regenerative medicine company with a proprietary stem cell-based tissue engineering technology platform that offers personalised, curative therapies for a range of severely debilitating, chronic diseases where there are no current gold standard treatments.</p> <p>Targeting the growing need for regenerative reparative therapies for serious and life-threatening diseases, Videregen’s leading programmes are focused on the development of an airways portfolio of orphan medicinal products with the lead indication targeting bronchial repair. Clinical proof of concept and initial safety in man has demonstrated the technology platform in some compassionate use cases.</p> <p>Videregen’s patented technology is being applied to the development of other organ replacement products, where the company is progressing preclinical development activities.</p>

<b>Oral Presentation</b>	<b>Title of Presentation / 講演タイトル</b>
	Personalised Regenerative Medicine: Bringing Tissue Repair to Life
	<b>Abstract / 要旨</b>
<b>Oral Presentation</b>	<p>Videregen is a leader in the development of personalised, regenerative products to replace, repair and restore organs and tissues.</p> <p>We are a clinical-stage regenerative medicine company using our proprietary technology platform to develop a range of personalised regenerative products targeting chronic, serious and orphan indications.</p> <p>Targeting the growing need for regenerative therapies for serious and life-threatening diseases, Videregen’s leading programmes are focused on the development of a portfolio of orphan medicinal products with a lead indication targeting life threatening complications following lung surgery.</p> <p>The Company’s patented technology and know-how is also being applied to the development of other organ and tissue replacement products; including airways, gastrointestinal, hepatic and immunological indications, targeting markets totaling more than \$2bn.</p> <p>The Company uses a proprietary stem-cell based technology platform to develop personalised, non-immunogenic tissue engineered therapy products based on biological scaffolds. The decellularised organ architecture provides a universal donor scaffold which is then repopulated with the patient’s own stem cells. Once implanted, through the process of matrix-guided tissue regeneration and the influence of the stem cells, the patient’s cells regenerate and restore functional tissue bespoke to the patient.</p> <p>Once initial first-in-man patient data is available, the Company will seek to expand regulatory and market access discussions in Japan and other regions. Investigations and preparations are already underway to prepare the foundations for future development in Japan leading to clinical trials, collaborations, joint ventures or license agreements to facilitate market entry.</p>

**Objectives and/or Motives / 目的**

Our objectives at the Regenerative Medicine Crossroads meetings is to explore partnerships, collaborations, licensing opportunities and fundraising in Japan to facilitate future market access for our products. In parallel to our UK and EU clinical trials, we would like to initiate Japanese clinical development. To aid this we have commissioned and completed a review of the regulatory pathway in Japan (performed by CMIC) and have identified a contract manufacture partner (MEDINET). Consequently, we are interested in partnering with Japanese regenerative medicine or pharma companies to collaborate on product development for the Japanese market.

The projects we are seeking partners for are tissue engineered regenerative medicine products to treat a range of airways diseases, these include our lead product for bronchopleural fistula and tracheal replacement.